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Abstract
The longitudinal course of ICBs in patients with Parkinson’s disease (PwP) relative to controls has not been explored as of 
yet. The aim of this study is to determine the frequency, evolution and associated cognitive and clinical features of impulsive 
and compulsive behaviors (ICBs) over 4 years of prospective follow-up in a population-based cohort with early Parkinson’s 
disease (PD). We recruited 124 cognitively intact participants with early PD and 156 matched controls from the Norwegian 
ParkWest study. ICBs were assessed using the self-report short form version of the Questionnaire for Impulsive–Compulsive 
Disorders in PD. Cognitive changes were examined in PwP with and without ICBs who completed the 4-year follow-up. 
Generalized linear mixed modelling and mixed linear regression were used to analyze clinical factors and cognitive changes 
associated with ICBs in PwP over time. ICBs were more common in PwP than controls at all visits, with an age-adjusted 
odds ratio (OR) varying between 2.5 (95% CI 1.1–5.6; p = 0.022) and 5.1 (95% CI 2.4–11.0; p < 0.001). The 4-year cumula-
tive frequency of ICBs in PwP was 46.8% and 23.3% developed incident ICBs during the study period, but the presence of 
ICBs was non-persistent in nearly 30%. ICBs were independently associated with younger age (OR 0.95, 95% CI 0.91–0.99: 
p = 0.008) and use of dopamine agonist (OR 4.1, 95% CI 1.56–10.69). Cognitive changes over time did not differ between 
patients with and without ICBs. In conclusion, ICBs are common in PwP, but are often non-persistent and not associated 
with greater cognitive impairment over time.
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Introduction
Impulsive and compulsive behaviors (ICBs) are common 
complications of dopaminergic replacement therapy (DRT) 
in Parkinson’s disease (PD), affecting between 13 and 30% 
of patients [10, 34]. ICBs encompass several addiction-like 
disorders related to reward-based activities, such as gam-
bling, sexuality, shopping and eating. In addition, patients 
also report behavioral subtypes that are uncommon in the 
general population, such as hobbyism, punding, walkabout 
and dopaminergic medication overuse.
ICBs are more prevalent in people with PD (PwP) than 
normal controls (NCs) [10], and the initiation of DRT—par-
ticularly dopamine agonists (DAs)—has been suggested as 
the main risk factor for development of these symptoms [19]. 
This is supported by several observations, for example, simi-
lar frequencies of ICBs reported in clinical studies of drug-
naïve PwP and NCs, presence of ICBs in medicated PwP 
is associated with DA use in several cohorts, and increased 
risk-taking behavior among DA users in experimental “on” 
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state studies [2, 3, 6, 10, 19, 30, 34]. ICBs are often seen in 
young PwP, probably because DA is more often prescribed 
in younger versus older PwP during the initial phases of 
PD treatment [17, 31, 34]. DAs are often down-titrated or 
discontinued during the course of PD due to the emergence 
of side effects, like nausea, sleep disorders or dyskinesia. 
Consequently, the frequency of ICBs could be expected to 
decrease over time. However, this hypothesis has only been 
explored empirically in one previous publication, highlight-
ing the need for further studies, and in particular studies that 
include controls [7].
ICBs have been associated with altered performance on 
executive tasks like set-shifting, reward-related decision 
making and concept formation [17, 26]. These findings are 
further supported by studies using neuroimaging, that dem-
onstrate neuroanatomical differences and disrupted func-
tional brain connectivity in mesolimbic and frontostriatal 
areas crucial for affective and reward processing [18]. Other 
cognitive domains, such as memory, visuospatial function-
ing, attention and language seem to be unaffected by ICBs, 
although this has been contested [26]. These observations 
have received support from a recent longitudinal study of 
cognition in PwP with ICBs [27], demonstrating that PwP 
and ICBs have relatively preserved executive functioning 
compared with PwP without ICBs over a mean follow-up 
period of 3.5 years. Similar findings were evident across 
several other cognitive domains, especially working memory 
[26].
The evolution of ICBs in PD is largely unknown, espe-
cially in later PD stages [2, 4, 7, 15, 16, 27, 28]. So far, 
no longitudinal studies have included controls and only 
one [27] had cognitive measures at follow-up. In addition, 
most studies were convenience samples, thereby limiting 
the generalizability of their findings. Thus, further studies 
using well-designed, population-based cohorts are needed. 
In the present study, we aim to (1) determine the longitudi-
nal course and incidence of ICBs in PwP and controls, (2) 
examine associated clinical factors of ICBs in PD over time, 
and (3) describe the cognitive changes of PD patients with 




PwP and controls were recruited from the Norwegian Park-
West study, an ongoing population-based, prospective cohort 
study of the incidence, neurobiology and prognosis of PD. A 
full overview of the diagnostic and recruitment procedures 
has been published elsewhere [1]. In short, a comprehen-
sive strategy for case ascertainment was used to recruit a 
population-based sample of 212 participants with incident 
PD and 205 controls from four counties in Western Norway 
were enrolled in the study between November 1st, 2004, 
and August 31st, 2006. After baseline assessment, move-
ment disorders neurologists initiated dopaminergic medica-
tion and evaluated participants clinically every 6 months. In 
addition, both PwP and controls were followed prospectively 
using standardized examinations of neuropsychiatric and 
cognitive functioning. This evaluation schedule was com-
pleted at baseline, 1 year follow-up, and thereafter every 
other year. Of 196 drug-naïve PwP at baseline, 20 were re-
diagnosed during follow-up. Also, three controls developed 
incident PD during the follow-up period, and were excluded. 
Evaluation of ICBs was first introduced 5 years after the 
baseline visit, wherein 129 PwP without dementia and 160 
controls without dementia participated. Of these, five PwP 
and four controls did not respond to ICB measures, yielding 
a cohort of 124 PwP and 156 controls eligible for this lon-
gitudinal study of ICBs. All PwP met the United Kingdom 
PD Society Brain Bank criteria for PD [14]. Signed written 
informed consent was obtained from all participants. The 
study was approved by the Regional Committee for Medical 
and Health Research Ethics, Western Norway.
Procedures
All participants underwent a standardized examination 
program administered by trained members of the ParkWest 
study group. Information on demographic variables, lifestyle 
factors, clinical history and medication were gathered using 
semistructured interviews. Motor severity and disease stage 
were assessed by the Unified PD Rating Scale (UPDRS) 
and Hoehn and Yahr scale, respectively. Levodopa equiva-
lent doses (LEDs) were calculated according to published 
recommendations [29].
Presence of ICBs was assessed using the self-report short 
form version of the Questionnaire for Impulsive–Compul-
sive Disorders in PD (QUIP) [33]. In accordance with pub-
lished recommended cutoff scores, participants with positive 
responses to one or more screening questions of the QUIP 
were classified to have ICB.
Depressive symptoms was assessed using the Montgom-
ery and Aasberg Depression Rating Scale (MADRS) [20]. 
Global cognitive function was assessed using the Mini-
Mental State Examination (MMSE) [11]. In addition, a 
neuropsychological test battery was administered to assess 
cognitive functioning in four domains: (1) executive func-
tioning (Semantic verbal fluency test [5] and Stroop interfer-
ence condition [12]) (2) verbal memory (immediate recall, 
short-delay recall and long-delay recall from the California 
Verbal Learning Test II [8]) (3) visuospatial skills (Silhou-
ette and Cube subtests of the Visual Object and Space Per-
ception Battery [32]), and (4) attention (Stroop word reading 
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and color naming test [12]). Both PwP and controls under-
went cognitive testing at follow-up. A composite score for 
each domain was calculated as the average of the test scores 
after conversion into percent of maximum possible (POMP) 
scores, of which the maximum values were defined accord-
ing to the maximum test scores of the NC group and the 
minimum values were set to zero. PD-associated dementia 
was diagnosed according to published criteria [9].
Categorizing of ICBs
Presence and development of ICB symptoms for PwP were 
categorized as follows: (1) no ICBs include patients who 
never reported ICBs during the study period (2) persistent 
ICBs include those who reported ICBs at two or more fol-
lowing visits, including the last follow-up (3) fluctuating 
ICBs include patients who reported at least one reversion 
from ICBs to no ICBs, and (4) uncategorized ICBs include 
those with incident ICBs at the last visit only (either 2 or 4 
years of follow-up).
Statistical analyses
All statistical analyses were conducted using IBM SPSS Sta-
tistics for Windows, Version 24.0.0.1 (Armonk, NY: IBM 
Corp.). Group differences were analyzed using t tests and 
Mann–Whitney tests for continuous variables, and Pearson 
χ2 tests for categorical variables. Two-tailed p values < 0.05 
were considered statistically significant.
Age-adjusted odds ratios (ORs) with 95% confidence 
intervals (CIs) for ICBs at each time of measurement were 
calculated using logistic regression. In these analyses, ICB 
status was used as dependent variable, while participant (PD 
or NC) and age was entered as independent variables.
Generalized linear mixed modelling (GLMM) was per-
formed to investigate factors associated with ICBs in PD 
over time. The main parameter of interest was the fixed 
effect of DA use over time. In this analysis, ICB status was 
used as dependent variable and age, sex, disease duration, 
DA use and follow-up time were fitted as fixed effects. For 
repeated measures (ICB status), a scaled identity covariance 
structure was assumed, as this covariance structure yielded 
the least amount of error and best model fit [evaluated using 
Akaike’s information criteria (AIC) and Schwarz’s Bayes-
ian criterion (BIC)]. Random intercept and slope were also 
included as they enhanced the model fit. A similar model 
using total LED instead of DA use was also fitted.
Neuropsychological performance was analyzed for 
patients that remained in the study after 4 years (n = 92), 
using mixed linear regression with scaled identify corre-
lational structure. In these analyses, neuropsychological 
performance was used as dependent variable and age, sex, 




Characteristics of patients and controls at initial ICB assess-
ment have been presented previously [10], and are summa-
rized in Table 1. Briefly, patients had less education and 
demonstrated lower MMSE and higher MADRS scores than 
the NC group.
Study flow
The flow of participants is available in online resource 1. 
Of 124 PwP and 156 controls, 17 PwP (3 withdrew and 14 
died) and 20 controls (9 withdrew and 11 died) were lost 
to follow-up. A total of 22 PwP were diagnosed with PD 
dementia during follow, and 1 patient and 2 controls were 
excluded due to missing data.
Evolution and course of ICBs
Frequency of ICBs for patients and controls during the 
study period is presented in Fig. 1. Compared to controls, 
patients displayed more ICBs at each visit. The age-adjusted 
OR ranged from 3.4 (95% CI 1.8–6.5; p < 0.001) at initial 
Table 1  Demographic and clinical characteristics at initial ICB 
assessment
Bold indicates p values < 0.05
PwP people with Parkinson’s disease, UPDRS Unified Parkin-
son’s Disease Rating Scale, MMSE Mini-Mental State Examination, 
MADRS Montgomery and Aasberg Depression Rating Scale, DA 
dopamine agonist, LED levodopa equivalent dosage
a Among DA users; patients using only levodopa were excluded from 
analysis
b Among levodopa users; patients using only DA were excluded from 
analysis
Characteristics PwP (N = 124) Controls (N = 156) p value
Age 70.4 (9.3) 70.2 (9.1) 0.864
Male, n (%) 76 (61.3) 82 (52.6) 0.144
Education, years 11.3 (3.3) 12.1 (3.5) 0.042
UPDRS motor score 22.7 (10.7) – –
PD duration, years 7.4 (1.7) – –
MMSE score 27.8 (2.5) 28.8 (1.5) 0.001
MADRS score 3.8 (4.4) 1.5 (2.9) 0.001
DA users, n (%) 77 (62.1) – –
Levodopa users, n (%) 102 (82.2) – –
Total  LEDa 612.7 (346.2) – –
DA  LEDa 182.5 (179.7) – –
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assessment, to 5.1 (95% CI 2.4–11.0; p < 0.001) after 2 years, 
and 2.5 (95% CI 1.1–5.6; p = 0.022) at the 4-year follow-up. 
During the 4-year follow-up, 58 of 124 patients (46.8%) and 
28 of 156 controls (17.9%) reported ICBs, yielding an age-
adjusted OR of 4.2 (95% CI 2.4–7.4; p < 0.001). Overall, 
20 of 86 patients (23.3%) and 10 of 138 controls (7.2%) 
developed incident ICBs during the 4-year study period, 
corresponding to an OR of 4.3 (95% CI 1.9–9.8; p < 0.001). 
Multiple ICBs were reported by 8.9% (11/124) of patients 
and 1.3% (2/156) of controls at initial assessment, 13.3% 
(14/105) and 2.2% (3/136) at 2-year follow-up, and 3.7% 
(3/82) and 3.2% (4/126) at 4-year follow-up, respectively. 
The frequencies of the individual ICB types are available in 
the online resource 2.
The course for different ICB categories in patients is pre-
sented in Fig. 2. A total of 105 patients had at least one 
follow-up visit after the initial assessment. Of these, 49.5% 
never reported ICBs, 13.3% had persistent and 28.6% non-
persistent symptoms, while 8.6% reported ICBs at the last 
visit only. A detailed presentation of the occurrence and 
development of ICBs is presented in online resource 3.
Associated clinical features
The cross-sectional association between ICB status and 
demographic and clinical variables is summarized in 
Table 2. In brief, ICB status was associated with lower age 
at each visit. DA use was associated with ICB status at the 
initial assessment and 2-year follow-up, but not at 4 years of 
follow-up. MADRS score was associated with ICB status at 
the initial assessment only.
Longitudinal analysis using GLMM showed significant 
fixed effects of age (F(1,6) = 7.0, p = 0.008) and DA use 
(F(1,6) = 8.2, p = 0.004), see Table 3 for a summary of this 
model. DA use was associated with increased risk of ICBs 
with an estimated OR of 4.1 (95% CI 1.56–10.69; p = 0.004), 
while higher age was associated with lower risk of ICBs (OR 
0.95, 95% CI 0.91–0.99; p = 0.008). ICBs were not associ-
ated with PD duration, sex or follow-up time. The fixed esti-
mate for the interaction time × DA use was not significant. 
This model predicted 86.8% of ICB cases. Repeating this 
model with levodopa use instead of DA use did not dem-
onstrate a significant effect of levodopa, while lower age 
remained significantly associated with ICB status.
Cognitive features
Change in MMSE and POMP scores for all four cognitive 
domains was not associated with ICB status over time. A 
detailed account of the results of each mixed linear regres-
sion model is available in the supplemental material (E-4).
Fig. 1  Frequencies of ICDs and related behaviors among patients with PwP and controls during the course of four years. ICD impulse control 
disorders, PwP people with Parkinson’s disease
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Discussion
In this prospective longitudinal study of a population-
based cohort of patients with PD, 47% of patients reported 
ICBs during the 4-year follow-up period. The 4-year 
cumulative incidence of ICBs was 23%. Occurrence of 
ICBs was consistently higher in patients with PD, with 
a more than fourfold increased risk of ICBs in PD com-
pared to well-matched controls during follow-up. Among 
patients with at least one follow-up visit, ICBs resolved in 
nearly 30%, while 13 % had persistent symptoms during 
follow up. Presence of ICBs was associated with DA use 
and younger age, but not with greater cognitive decline 
over time. Although these findings demonstrate that ICB 
symptoms often resolve over time, they also underscore 
the need for continued clinical assessments of ICBs during 
the course of PD, as incident ICBs are also observed in the 
later stages of the disease.
The prevalence of ICBs decreased from around 30% at 
initial assessment to 22% after 4 years. During the same fol-
low-up period, the proportion of DA users decreased about 
10% and the proportion of levodopa users increased almost 
equivalently. These findings are consistent with a recent 
multicenter open-label trial reporting alleviation of ICBs 
in PD patients 12 weeks after switching from DAs to levo-
dopa/carbidopa slow-release formulations. Still, more than 
half of our patients with ICBs were using DA at every visit. 
Possible explanations for this include underreporting of 
ICB symptoms in clinical practice and motor worsening or 
withdrawal syndrome during tapering or discontinuation of 
DA therapy [24]. Unfortunately, our study was not designed 
to address this issue. As opposed to the present study, one 
Fig. 2  Flow chart of patients, 
stratified according the ICB 
status. ICB impulsive–compul-
sive behaviors
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large longitudinal multicenter study recently showed that 
ICB prevalence increased from around 20% to nearly 33% 
after 5 years of follow-up [7]. However, this PD cohort was 
characterized by a high prevalence of DA treatment, which 
may also explain the high 5-year cumulative incidence of 
ICB around 46%. In comparison, the cumulative incidence 
of ICB in our cohort was about 50% lower after 4 years of 
follow-up.
To our knowledge, this is the first longitudinal study of 
ICBs in PD that includes NCs. We found a more than four-
fold increased risk of prevalent and incident ICBs during 
the 4-year follow-up period. This finding support the results 
of a recent meta-analysis showing that PD patients have a 
twofold increased risk of ICBs compared with controls [19].
Our data confirm and expand numerous previous findings 
from cross-sectional [2, 34] and longitudinal studies report-
ing a strong association between DA usage and presence 
of ICBs in PD [4, 7, 15, 16, 27, 28]. Although our findings 
argue that the association between ICBs and DA use may be 
a class effect, clinical experience and long-term studies indi-
cate a dose–effect relationship between ICBs and DAs [7], 
and the first treatment option is often to reduce DA dosage 
while stepping up the dosage of levodopa [16, 35]. Although 
some previous cross-sectional studies suggest an association 
between levodopa and ICBs [34], other longitudinal stud-
ies [4, 7], including ours, do not confirm this assumption. 
One should keep in mind that ICBs probably resolve slowly 
after DAs are discontinued, and that this may erroneously 
suggest an association between levodopa and ICBs even 
though ICBs appeared before levodopa was started or doses 
increased [7]. Also, for some patients discontinuation of DA 
might be necessary to ensure alleviation of ICB symptoms.
Even though the frequency of ICBs may diminish over 
time, there are still ample reasons for continued clini-
cal screening of ICBs during the course of PD. As dem-
onstrated recently, time to onset of ICB symptoms varies 
greatly following DA treatment [4]. In our study, new cases 
of ICBs emerged more than 5 years after PD was diagnosed. 
Table 2  Clinical features stratified by ICB status in PwP during follow-up
PwP people with Parkinson’s disease, ICB impulsive and compulsive behaviors, UPDRS Unified Parkinson’s Disease Rating Scale, MADRS 
Montgomery and Aasberg Depression Rating Scale, LED levodopa equivalent dose, DA dopamine agonist. Univariate group differences indi-
cated by: *p < 0.05; **p < 0.001
a Dyskinesia as defined by score ≥ 1 on UPDRS item 32
b Among DA users; patients using only levodopa were excluded from analysis
c Among levodopa users; patients using only DA were excluded from analysis
Characteristics Baseline (N = 124) 2-year follow-up (N = 105) 4-year follow-up (N = 82)
ICBs (N = 38) Non-ICBs (N = 86) ICBs (N = 32) Non-ICBs (N = 73) ICBs (N = 18) Non-ICBs (N = 64)
Age, year 67.9 (7.7) 71.5 (9.8)* 66.7 (8.7) 72.9 (8.6) ** 68.4 (10.1) 73.8 (8.7) *
Male, n (%) 26 (68.4) 50 (56.3) 21 (67.7) 38 (51.4) 13 (72.2) 31 (48.4)
UPDRS motor score 23.8 (10.5) 22.3 (10.8) 21.9 (9.7) 23.2 (11.6) 25.6 (13.2) 24.6 (12.7)
Dyskinesiaa, n (%) 8 (21.1) 10 (11.6) 10 (31.3) 16 (22.0) 5 (27.8) 24 (37.5)
PD duration, year 7.4 (1.6) 7.3 (1.8) 9.3 (1.6) 9.3 (1.7) 11.4 (2.2) 11.1 (1.5)
MADRS score 5.4 (5.1) 3.1 (3.9) * 5.6 (5.7) 4.4 (4.5) 4.8 (7.2) 5.3 (5.0)
DA users, n (%) 32 (84.2) 45 (52.9) ** 25 (68.8) 37 (50.7) * 10 (55.6) 33 (51.6)
Levodopa users, n (%) 29 (76.3) 74 (85.1) 28 (87.5) 67 (91.8) 18 (100.0) 57 (89.1)
Total  LEDb 731.2 (342.0) 658.2 (282.3) 956.9 (507.6) 798.5 (324.0) 1195.1 (527.9) 936.2 (410.9)
DA  LEDb 293.7 (132.4) 285.9 (149.7) 316.1 (131.1) 326.3 (142.7) 267.2 (154.3) 333.8 (132.0)
Levodopa  dosec 505.2 (279.1) 410.3 (268.3) 590.2 (327.4) 485.2 (262.2) 634.7 (386.9) 544.7 (282.3)
Table 3  Effect estimates of generalized mixed regression models with 
ICB status as dependent variable
ICB impulsive and compulsive behaviors, DA dopamine agonist, PD 
Parkinson’s disease, SE standard error, CI confidence interval
*p ≤ 0.05; **p ≤ 0.01; p ≤ 0.001
a With male gender set as reference category
b With “no DA use” set as reference category
Outcome Effects OR SE 95% CI for OR
ICB status Main effects group
 Sexa − 0.31 0.39 (− 1.08, 0.45)
 Age − 0.06** 0.02 (− 0.10, − 0.02)
 PD duration 0.10 0.11 (− 0.11, 0.31)
 Time 0.06 0.14 (− 0.22, 0.34)
 DA  useb 1.41** 0.49 (0.44, 2.37)
Interaction, time × DA use
 Time × DA  useb − 0.29 0.17 (− 0.63, 0.05)
Random effects
 Residual effect 0.65*** 0.07 (0.53, 0.79)
 Random intercept 1.95*** 0.54 (1.13, 3.36)
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However, ICB presence was generally unstable and we can-
not exclude that some patients with incident ICBs may have 
experienced such symptoms before the start of the pre-
sent study. As such, our ICB remission rate is probably an 
underestimation. Other studies have reported substantially 
higher ICB remission rates, but this seems to vary consider-
ably due to differences in sample sizes and methodological 
approaches [16]. Other explanations for the non-persistent 
nature of ICBs include the risk identifying sub-syndromal 
ICBs when utilizing QUIP, a methodological issue that 
could be addressed by also administering QUIP to the car-
egivers of the patients [23].
Our data suggest that ICB status in not related to greater 
cognitive impairment over time. Although these findings 
conflict with several studies investigating specific dopa-
mine-sensitive executive functions, like risk assessment and 
decision making [6, 30], the lack of cognitive dysfunctions 
in other cognitive domains is consistent with reports from 
other cohorts investigating the association between ICBs 
and global cognitive functioning [3, 27, 31]. Data obtained 
after dementia onset were excluded in those who devel-
oped PD dementia during follow-up. This procedure could 
skew the estimates of POMP scores over time and thereby 
underestimate the cognitive decline of patients with ICBs. 
However, the rate of incident dementia at follow-up was not 
different between ICB-positive and ICB-negative patients at 
study start (data not shown), arguing that self-censoring of 
demented patients did not affect the results. This is further 
supported by the association between ICBs and younger age 
in our study.
Preserved cognitive functioning in patients with ICBs is 
also of clinical importance, especially for potential develop-
ment of new management strategies for ICBs in PD. The 
current management strategy for ICBs is alterations of DRT, 
an approach not viable in all cases [36]. Alternative treat-
ments have been suggested, including cognitive behavioral 
therapy [21, 22], a psychotherapeutic treatment commonly 
used in the treatment of ICBs in the general population [13, 
25]. Although promising, the efficacy of CBT is contingent 
on relatively preserved cognitive functioning. Thus, the 
findings of this study provides an argument for continued 
research and development of CBT for PwP and ICBs.
The major strengths of our study include the population-
based design, limited attrition during follow-up, well-char-
acterized PD cohort and inclusion of controls from the same 
geographical area. There are also some limitations of this 
study. First, the sample is limited in size. Although this issue 
could result in less statistical power, the use of conservative 
statistical procedures decreases the risk of type II errors. 
Second, the use of QUIP may overestimate the frequency 
of ICBs. This issue has been highlighted in several previous 
publications, and the inclusion of semistructured interviews 
would probably result in lower risk of false positives. Still, 
the risk of inflated frequency estimates is similar in PwP and 
controls, and would therefore not influence the ORs of this 
study. In addition, the frequency estimates of this study are 
comparable to other studies gauging the full scope of ICBs. 
Finally, the neuropsychological test battery utilized in this 
study provides limited insights into specific executive func-
tions previously associated with ICBs, such as risk assess-
ment and set-shifting. However, this study provides valuable 
insights into several global indices of cognitive functioning, 
such as verbal memory, attention and visuospatial function-
ing. These cognitive domains are important determinants of 
global cognitive functioning, and essential when assessing 
cognitive decline in PwP.
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